Novel Alzheimer’s Therapies Given to Less than 20 Pct of Applicants
Tokyo, April 8 (Jiji Press)–Novel Alzheimer’s therapies have been given to 19 pct of outpatients who applied for the medications, according to a recent survey at a Tokyo hospital. The lecanemab and donanemab therapies for early-stage Alzheimer’s patients are now clinically available